UTHR United Therapeutics Corporation
USHealthcareAs of 2026-07-09 16:00
Why UTHR matters now
United Therapeutics Corporation (UTHR) is a US stock in Healthcare. The latest InvestLog snapshot shows $552.48 with -0.34% on the session and $23.45B in market capitalization; recent performance reads 1-month -5.33% and YTD +10.13%.
The latest financial table shown here is Q1 2026, with revenue of $781.5M, net income of $274.9M, and EPS of $5.82. Investors can compare that operating picture with valuation signals such as P/E 18.58 and FCF yield 4.5%.
The latest indexable market news headline is "United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $635.00; recent insider activity includes MAHON PAUL A filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
18.58
PEG
1.59
P/B
3.96
P/S
7.19
EV/EBITDA
12.67
DCF Value
$804.61
FCF Yield
4.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
86.6%
Operating Margin
45.3%
Net Margin
40.6%
ROE
19.2%
ROA
19.2%
ROIC
18.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $781.5M | $274.9M | $5.82 |
| Q4 2025 | $790.2M | $364.3M | $7.66 |
| FY 2025 | $3.18B | $1.33B | $27.86 |
| Q3 2025 | $799.5M | $338.7M | $7.16 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$636.83
Target (Median)
$635.00
Target Range
$516.00 - $735.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.57
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.